Clinical effect of Marvelon in treatment of abnormal uterine bleeding

Objective To investigate the clinical efficacy of Marvelon in the treatment of abnormal uterine bleeding(AUB)and its effects on serum follicle stimulating hormone(FSH), estradiol(E₂), and luteinizing hormone(LH)levels. Methods A total of 90 patients with AUB who were treated in gynecology department in our hospital were divided into control group and observation group according to random number table method, with 45 cases per group, and were given Mifepristone and Marvelon, respectively. The clinical efficacy, hemostatic effect, hormone levels, and incidence of adverse reactions before and after treatment were compared between the two groups. Results The total clinical effective rate was 93.33% in the observation group, which was significantly higher than 71.11% in the control group(P<0.05). The bleeding control time and complete hemostasis time in the observation group were significantly shorter than those in the control group(P<0.05). The levels of serum FSH, LH and E₂ after treatment in the two groups were significantly lower than before treatment(P<0.05), and the reduction of serum sex hormone levels in the observation group after treatment was significantly greater than in the control group(P<0.05). In the course of treatment, liver and kidney functions related adverse reactions did not occur in these patients, and only a few patients presented mild nausea and dizziness without affecting the treatment. Conclusion Marvelon can inhibit the release of FSH in the serum of AUB patients, and promote the reduction of endogenous E₂ and LH levels, which has an excellent function in regulating sex hormone, significant clinical efficacy as well as higher safety. Therefore, it can be used as a preferred program in clinical treatment of AUB.